← Browse by Condition
Medical Condition

head and neck squamous cell carcinoma

Total Trials
18
Recruiting Now
18
Trial Phases
Phase 2, Phase 1, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for head and neck squamous cell carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — head and neck squamous cell carcinoma Clinical Trials

How many clinical trials are currently recruiting for head and neck squamous cell carcinoma?
ClinicalMetric currently tracks 18 actively recruiting clinical trials for head and neck squamous cell carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 18. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for head and neck squamous cell carcinoma?
head and neck squamous cell carcinoma research spans Phase 1 (6 trials), Phase 2 (7 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a head and neck squamous cell carcinoma clinical trial?
Eligibility criteria for head and neck squamous cell carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
6
Phase 2
7
Top Sponsors
CSPC Megalith Biopharmaceutical Co.,Ltd. 1 trial
University of Maryland, Baltimore 1 trial
Memorial Sloan Kettering Cancer Center 1 trial
Lepu Biopharma Co., Ltd. 1 trial
Wake Forest University Health Sciences 1 trial

Recruiting Clinical Trials

NCT07254585 Phase 2
Recruiting
SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma
Enrollment
70 pts
Location
China
Sponsor
CSPC Megalith Biopharmaceutica...
View Trial →
NCT06088381 Phase 2
Recruiting
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
Enrollment
61 pts
Location
United States
Sponsor
University of Maryland, Baltim...
View Trial →
NCT05859074 Phase 1
Recruiting
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Enrollment
56 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
View Trial →
NCT07586124 Phase 2
Recruiting
Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma
Enrollment
80 pts
Location
China
Sponsor
Lepu Biopharma Co., Ltd.
View Trial →
NCT04375384 Phase 2
Recruiting
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
Enrollment
38 pts
Location
United States
Sponsor
Wake Forest University Health ...
View Trial →
NCT06081673 Phase 2
Recruiting
Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC
Enrollment
72 pts
Location
China
Sponsor
Shanghai Ninth People's Hospit...
View Trial →
NCT06662058
Recruiting
Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Enrollment
118 pts
Location
United States
Sponsor
Emory University
View Trial →
NCT03406247 Phase 2
Recruiting
Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma
Enrollment
140 pts
Location
France
Sponsor
Gustave Roussy, Cancer Campus,...
View Trial →
NCT05877599 Phase 1
Recruiting
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Enrollment
45 pts
Location
United States
Sponsor
AstraZeneca
View Trial →
NCT07105592 Phase 1, Phase 2
Recruiting
A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma
Enrollment
68 pts
Location
China
Sponsor
Fudan University
View Trial →
NCT05031910
Recruiting
Virtual Reality 3D-Surgery Modeling to Enhance Head and Neck Cancer Surgery Quality
Enrollment
160 pts
Location
United States
Sponsor
Thomas Jefferson University
View Trial →
NCT05983432 Phase 1
Recruiting
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Enrollment
470 pts
Location
United States, Franc...
Sponsor
SystImmune Inc.
View Trial →
NCT02678884
Recruiting
Head and Neck Squamous Cell Carcinoma (HNSCC)PET-CT Pilot Study
Enrollment
20 pts
Location
Canada
Sponsor
University Health Network, Tor...
View Trial →
NCT06163534
Recruiting
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Enrollment
500 pts
Location
United States, Puert...
Sponsor
Tempus AI
View Trial →
NCT05047094
Recruiting
Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC
Enrollment
48 pts
Location
Israel
Sponsor
Alpha Tau Medical LTD.
View Trial →
NCT05793151
Recruiting
Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy
Enrollment
532 pts
Location
United States
Sponsor
Medical University of South Ca...
View Trial →
NCT07216105 Phase 1
Recruiting
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Enrollment
119 pts
Location
United States
Sponsor
Fate Therapeutics
View Trial →
NCT04429542 Phase 1
Recruiting
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Enrollment
292 pts
Location
United States, Austr...
Sponsor
Bicara Therapeutics
View Trial →

Related Conditions

metastatic head and neck squamous cell carcinoma (3) non small cell lung cancer (3) breast cancer (3) ovarian cancer (3) head and neck cancer (2) oropharynx cancer (2) cutaneous squamous cell carcinoma (2) recurrent head and neck squamous cell carcinoma (2) colorectal cancer (2) oropharynx squamous cell carcinoma (1) hpv positive oropharyngeal squamous cell carcinoma (1) scc squamous cell carcinoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology